Sanofi Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service Following Novartis, Boehringer, and Roche, Sanofi is now CATALIS’ fourth pharmaceutical partner to pilot its FAST TRACK Evaluation Service. Sanofi’s Phase I-ll study, which uses human subjects for the first time and is designed to assess the safety and the pharmacokinetic, pharmacodynamic, and antitumor activity
Roche Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service Thanks to CATALIS’ FAST TRACK evaluation service, Roche’s ProHer multi-centre study, which explores a new treatment method for patients with breast cancer, was approved in 10 weeks by the CHU de Québec-Université Laval. More specifically, this study seeks to discover patients’ preference for at-home administration
CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform CATALIS Quebec is very proud to partner with N2 Canada to provide its Network member healthcare institutions access to a shared training platform designed to ensure the conduct of high-quality research: the CITI-Canada training platform. Through this partnership, CATALIS Quebec officially becomes the new
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service While the first-ever FAST TRACK evaluation service pilot project was successfully completed last December, CATALIS is proud to announce that two more clinical trials have now been approved in record time. The second FAST TRACK evaluation service coordinated a Phase I oncology study
Launch of New Shared Clinical Research Tools CATALIS and its network of public and private partners have facilitated the implementation of new shared tools designed to optimize the launching and conducting of clinical trials in Quebec; more specifically, CATALIS has coordinated the revision of documents serving to optimize the contract negotiation process with private industry and a memo which serves to
Danika Laberge Has Been Appointed President and Chief Executive Officer of CATALIS Quebec CATALIS Quebec’s Board of Directors is pleased to announce the appointment of Danika Laberge as the organization’s President and Chief Executive Officer (CEO). “It is with tremendous enthusiasm and confidence in her abilities that the Board of Directors has appointed Ms. Laberge to the position of
We’re looking for a Project Manager who will help implement and conduct activities related to the FAST TRACK evaluation service for clinical trials in Québec. To view the job offer, click here.
CATALIS Quebec’s Network of Partners Now Includes 23 Quebec Health Institutions In keeping with its new government mandate of bringing together clinical research stakeholders, CATALIS Quebec is pleased to announce that it is expanding the scope of its activities to a larger number of institutions in the province: it has added 23 public institutions from Quebec’s health and social
Two New Administrators Join the CATALIS Board of Directors Dr. Guy A. Rouleau Dr. Guy Rouleau is Director of The Neuro (Montreal Neurological Institute-Hospital), Chair of the Department of Neurology and Neurosurgery of McGill University, Director of the Department of Neuroscience of McGill University Health Centre, and co-founder of the Tanenbaum Open Science Institute. He was recently elected Vice-President of
In recognition of Dr. Jacques Michaud and Dr. Michael Sebag for their work on the CATALIS Quebec Board of Directors After three years on the CATALIS Board of Directors, Dr. Jacques Michaud is now stepping down. On behalf of the CATALIS Board of Directors, I would like to acknowledge Dr. Michaud’s professionalism and dedication, and to thank him for
From Creating Operational and Structural Bases to Establishing New Services: CATALIS Québec Reached New Heights in 2021 Now that 2021 has come to an end, I want to say how proud I am of CATALIS Québec’s achievements. I am impressed by our growing team’s accomplishments and the tremendous work its members did in a difficult context. We had to
A First Successful Pilot Project for CATALIS’ New FAST TRACK Evaluation Service: 4 Quebec Institutions Ranked in the Top 5 of the World’s Fastest Sites CATALIS is very proud to announce that the first pilot of its new FAST TRACK assessment service has successfully reduced the approval time for an industry-financed clinical trial by almost 75%. In September 2021,
Three Major Projects Mark the Start of the Patient Advisory Committee’s Operations Patient partners and 11 patient organizations representing various medical conditions are at the core of CATALIS Quebec’s new Patient Advisory Committee. This committee was mandated by CATALIS management to identify common issues and solutions that will facilitate patient engagement and increase patient participation in, and referrals to, clinical
Patient Partners and 11 Patient Organizations Have Joined CATALIS Québec CATALIS Québec and its partners want the patient’s voice to be heard in all facets of clinical research in Quebec. As a result, we are now working with patient organizations and patient partners from various therapeutic fields by including them on our new patient advisory committee. In carrying out
Me Jean Groleau Named Vice-President of the Board of Directors We are pleased to announce that Me Jean Groleau has been named Vice-President of the CATALIS Board of directors. Me Groleau is an experienced administrative and judicial tax litigation lawyer. He began his career in the Ministère du Revenu du Québec’s litigation department. He was then named partner at a
CATALIS is recruiting a Coordinator, Clinical Research Support Service SUMMARY OF THE POSITION Under the authority of the Director of public and patient engagement, the Coordinator, Clinical Research Support Service participates in the development, planning and implementation of the personalized support service in clinical research . As the service coordinator, the incumbent will be an important point of contact
CATALIS Begins Its Public And Patient Engagement Process Since last summer, CATALIS has been developing a patient component that will also complement the comprehensive, collaborative model that defines the organization’s mission. This model already has a wide range of life sciences industry stakeholders, such as the Ministry of Economy and Innovation, the Ministry of Health and Social Services, CATALIS network
The CATALIS Public-Private Network has developed a new FAST TRACK evaluation service that will eventually allow industry-funded clinical trials to be authorized in less than 8 weeks.
CATALIS is hiring! TITLE: Project Manager – Clinical Trials LOCATION: Montreal, QC INDUSTRY: NPO, Clinical trials Permanent position, full time SUMMARY OF THE POSITION Under the authority of the Director General, the Project Manager collaborates in activities related to the accelerated evaluation service for clinical trials in Quebec; and other operational activities of CATALIS. MAIN RESPONSIBILITIES • Assists the Managing
CATALIS is hiring! We are looking for a professional in communications inspired to develop promotional campaigns to inform the clinical research network. Under the authority of the CEO, the Senior Communications Advisor will participate in the development, implementation and monitoring of the organization’s communications and marketing activities. MAIN RESPONSIBILITIES • Develop, implement and monitor the organization’s communication and marketing activities:
CATALIS is launching a new call for applications to select public institutions that will receive 2 years of funding for their participation in CATALIS activities. Within the call for applications, public institutions that are members of the Table nationale des directeurs de recherche (TNDR) are invited to apply on 2 levels of clinical research activities: the implementation of automated tools
CATALIS is now implementing its new strategic plan with the creation of new advisory committees Since 2018, CATALIS’s operational activities have been guided essentially by an advisory committee composed of research centre administrators, pharmaceutical industry members, and government representatives. In 2021, given that the new strategic plan extends the scope of CATALIS’s actions, two new advisory committees will be created: a
CATALIS has great plans for the coming year. A message from the chairman of the CATALIS board of directors, Dr. Marc Rivière There is no doubt that this past year has been disconcerting and most unusual. Clinical research was confronted with substantial challenges that highlighted our system’s ability to adapt quickly and find innovative solutions. This exceptional situation caused us to
The Quebec Government’s 2020–2021 budget, tabled yesterday by Minister of Finance Éric Girard, mentions investments in the field of clinical research, a commitment that was favourably received by CATALIS Québec’s board of directors.